4-Aza-spiro[2.4]heptane-5-carboxylic acid | 124032-25-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-Aza-spiro[2.4]heptane-5-carboxylic acid
• 英文别名: 4-Azaspiro[2.4]heptane-5-carboxylic acid
• CAS: 124032-25-3
• 化学式: C₇H₁₁NO₂
• mdl: MFCD19223728
• 分子量: 141.17
• InChiKey: LQUHGXCDHRASRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-Aza-spiro[2.4]heptane-4,5-dicarboxylic acid 4-benzyl ester 在 碘代三甲硅烷 作用下， 以 乙腈 为溶剂， 以58%的产率得到4-Aza-spiro[2.4]heptane-5-carboxylic acid
  参考文献：
  名称：

  Synthesis of a new analog of proline

  摘要：

  DOI：

  10.1016/s0040-4039(00)95211-0

文献信息

• NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
  申请人：CHU Daniel

  公开号：US20090062268A1

  公开（公告）日：2009-03-05

  A compound having the structure set forth in Formula (I): wherein the variables Y, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Compounds described herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of such compounds and pharmaceutical compositions to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

  具有以下式（I）所示结构的化合物： 其中变量Y，R1，R2，R3，R4和R5如本文所定义。本文描述的化合物是聚(ADP-核糖)聚合酶活性的抑制剂。本文还描述了包括至少一种本文描述的化合物的药物组合物，以及利用这些化合物和药物组合物治疗通过抑制PARP活性而改善的疾病、疾病和症状。
• [EN] COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES IMMUNITAIRES ET INFLAMMATOIRES
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035408A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

  提供了化合物、使用方法以及制备补体因子D抑制剂的过程，这些抑制剂包括式I、I"和I'"或其药学上可接受的盐或组合物。本文所述的因子D抑制剂靶向因子D并抑制或调节补体级联反应。本文所述的因子D抑制剂减少了补体的过度激活。
• [EN] DISUBSTITUTED COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS DISUBSTITUÉS DESTINÉS AU TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035361A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula (I), or a pharmaceutically acceptable salt or composition thereof. The inhibitors of Factor D described herein reduce the excessive activation of complement, and are useful to treat disorders mediated by the complement system.

  提供了有关制备补体因子D抑制剂的化合物、使用方法和制备过程，包括化学式（I）或其药用盐或组合物。本文描述的因子D抑制剂可减少补体的过度激活，并可用于治疗由补体系统介导的疾病。
• PETTER, RUSSELL C., TETRAHEDRON LETT., 30,(1989) N 4, C. 399-402
  作者：PETTER, RUSSELL C.

  DOI：——

  日期：——
• [EN] NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)<br/>[FR] NOUVEAUX INHIBITEURS DE LA POLY(ADP-RIBOSE)POLYMÉRASE (PARP)
  申请人：LEAD THERAPEUTICS INC

  公开号：WO2009029375A1

  公开（公告）日：2009-03-05

  A compound having the structure set forth in Formula (I): wherein the variables Y, R1, R2, R3, R4 and R5 are as defined herein. Compounds described herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of such compounds and pharmaceutical compositions to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.